Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 17/20 | 0.58 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7285302 | 0.86 | ERN1 (0.62) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL28292328 | 0.81 | ERN1 (0.61) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL3645435 | 0.81 | ERN1 (0.61) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL28282933 | 0.81 | ERN1 (0.56) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL13855640 | 0.79 | ERN1 (0.55) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL118908 | 0.79 | ERN1 (0.68) | ERN1ALDH1A1LMNAMAPT | |
| SCHEMBL931983 | 0.79 | ERN1 (0.60) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL13980464 | 0.78 | ERN1 (0.53) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL4376307 | 0.78 | ERN1 (0.58) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL5647002 | 0.77 | ERN1 (0.53) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| EP-1996145-A2 | REDUCTIVE COLOUR REMOVAL | Henkel AG & Co. KGaA (DE) | 2008-12-03 | — | — | EP | claimed |
| EP-1888018-A1 | AGENTS FOR DYEING KERATIN-BASED FIBRES | Henkel Kommanditgesellschaft auf Aktien (DE) | 2008-02-20 | — | — | EP | claimed |
| EP-1879660-A1 | AGENT FOR DYEING KERATIN-BASED FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-01-23 | — | — | EP | claimed |
| EP-1838279-A1 | AGENTS FOR DYING KERATIN FIBERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-10-03 | — | — | EP | claimed |
| WO-2007107310-A2 | REDUCTIVE COLOUR REMOVAL | HENKEL AG & CO. KGAA (DE) | 2007-09-27 | — | — | WO | claimed |
| EP-1789007-A1 | PRODUCTS FOR DYEING KERATIN FIBERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006119819-A1 | AGENT FOR DYEING KERATIN-BASED FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-11-16 | — | — | WO | claimed |
| WO-2006119818-A1 | AGENTS FOR DYEING KERATIN-BASED FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-11-16 | — | — | WO | claimed |
| WO-2006077039-A1 | AGENTS FOR DYING KERATIN FIBERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-07-27 | — | — | WO | claimed |
| WO-2006029672-A1 | PRODUCTS FOR DYEING KERATIN FIBERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-03-23 | — | — | WO | claimed |
| CN-1606551-A | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH CORP (US) | 2005-04-13 | — | — | CN | claimed |
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2005-02-17 | — | — | US | claimed |
| EP-1458700-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-22 | — | — | EP | claimed |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2003-09-11 | — | — | US | claimed |
| WO-2003051860-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | claimed |
| US-9770432-B2 | Deuterated benzopyran compounds and the use in the treatment of pain and inflammation | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2017-09-26 | — | — | US | disclosed |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2003-09-11 | — | — | US | disclosed |
| WO-2003051860-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, ESRRA | ERN1 1373/4885TRIM24 3008/4885TYR 2670/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ERN1 3514/4885TRIM24 3299/4885TYR 363/4885 |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, GPER1 | ERN1 1313/4885TRIM24 2982/4885TYR 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.